203503-02-0

Basic information

• Product Name: 1-Piperidinecarboxylic acid, 4-azido-3-hydroxy-, 1,1-dimethylethyl ester
• CAS NO: 203503-02-0
• Molecular Formula: C10H18N4O3
• Molecular Weight: 242.278
• Mol File: 203503-02-0.mol

Chemical Properties

• CAS DataBase Reference: 1-Piperidinecarboxylic acid, 4-azido-3-hydroxy-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Piperidinecarboxylic acid, 4-azido-3-hydroxy-, 1,1-dimethylethyl ester(203503-02-0)
• EPA Substance Registry System: 1-Piperidinecarboxylic acid, 4-azido-3-hydroxy-, 1,1-dimethylethyl ester(203503-02-0)

Safety Data

• Hazardous Substances Data: 203503-02-0(Hazardous Substances Data)

Upstream product

• 85838-94-4 N-Boc-1,2,3,6-tetrahydropyridine 

Downstream Products

• 1331777-74-2 rac-(3S,4S)-tert-butyl 4-amino-3-hydroxypiperidine-1-carboxylate 
• 1431533-84-4 tert-butyl 4-((4-(cyclopropylmethoxy)benzoyl)amino)-3-hydroxypiperidine-1-carboxylate 
• 203503-03-1 4-amino-3-hydroxy-piperidine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

PYRROLO[2,3-D]PYRIMIDINYL, PYRROLO[2,3-B]PYRAZINYL AND PYR-ROLO[2,3-D]PYRIDINYL ACRYLAMIDES

The present invention provides pharmaceutically active pyrrolo[2,3-d]pyrimidinyl and pyrrolo[2,3-d]pyridinyl acrylamides and analogues thereof. Such compounds are useful for inhibiting Janus Kinase (JAK). This invention also is directed to compositions comprising methods for making such compounds, and methods for treating and preventing conditions mediated by JAK.

INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL

The present invention provides compounds of Formula (I) (Formula (I)) including pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.

BICYCLIC OXAZOLE AND THIAZOLE COMPOUNDS AND THEIR USE AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS

In one aspect, the invention relates to novel bicyclic oxazole and thiazole compounds which are positive allosteric modulators of the metabotropic glutamate receptor subtype 5 ("mGluR5"); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions; and methods for the treatment or prevention of disorders associated with glutamate dysfunction and diseases in which the mGluR5 subtype of receptors is involved. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.